{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:35:57Z","timestamp":1790760957684,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clml.2019.03.029","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:39:20Z","timestamp":1554118760000},"page":"555-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis"],"prefix":"10.1016","volume":"19","author":[{"given":"Divaya","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-7114","authenticated-orcid":false,"given":"Siyang","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.029_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.029_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.clml.2019.03.029_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib4","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jmb.2013.10.016","article-title":"Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations","volume":"426","author":"Blancas-Mej\u00eda","year":"2014","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.clml.2019.03.029_bib6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","article-title":"Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment","volume":"100","author":"Perfetti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib7","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","article-title":"Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)","volume":"101","author":"Abraham","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib9","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8","article-title":"Primary systemic amyloidosis with delayed progression to multiple myeloma","volume":"82","author":"Rajkumar","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.03.029_bib10","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib11","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clml.2019.03.029_bib12","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.029_bib13","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.029_bib14","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.03.029_bib15","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.clml.2019.03.029_bib16","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.029_bib18","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib19","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib21","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.029_bib22","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.029_bib24","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2019.03.029_bib25","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.03.029_bib26","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.clml.2019.03.029_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.clml.2019.03.029_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.echo.2017.08.017","article-title":"Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation","volume":"31","author":"Pun","year":"2018","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.clml.2019.03.029_bib29","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2019.03.029_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.clml.2019.03.029_bib31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2015-11-681650","article-title":"Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis","volume":"127","author":"Weiss","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib32","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4\u2032-iodo-4\u2032-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"92","author":"Merlini","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.03.029_bib33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V93.3.1112","article-title":"Treatment of AL amyloidosis with 4\u2032-iodo-4\u2032-deoxydoxorubicin: an update","volume":"93","author":"Merlini","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ajcp\/100.1.67","article-title":"Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies","volume":"100","author":"Abe","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2019.03.029_bib35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2019.03.029_bib36","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","article-title":"Radioimmunodetection of amyloid deposits in patients with AL amyloidosis","volume":"116","author":"Wall","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib37","first-page":"3831S","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.03.029_bib38","first-page":"509","article-title":"Final analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory al amyloidosis","volume":"130","author":"Edwards","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib39","series-title":"Improvement in global longitudinal strain (GLS) correlates with NT-ProBNP response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid Mab Cael-101. American Society of Hematology meeting","author":"Bhutani","year":"2018"},{"key":"10.1016\/j.clml.2019.03.029_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fimmu.2011.00032","article-title":"Generation and characterization of anti-AA amyloid-specific monoclonal antibodies","volume":"2","author":"Wall","year":"2011","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2019.03.029_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.clml.2019.03.029_bib42","doi-asserted-by":"crossref","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.03.029_bib43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.029_bib45","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2018-07-865857","article-title":"Beyond NEOD001 for systemic light-chain amyloidosis","volume":"132","author":"Varga","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib46","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","article-title":"Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer\u2019s disease and systemic amyloidosis","volume":"92","author":"Tennent","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.03.029_bib47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.amjmed.2005.08.043","article-title":"Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis","volume":"119","author":"Hazenberg","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2019.03.029_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","article-title":"Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis","volume":"148","author":"Gillmore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.029_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clml.2019.03.029_bib50","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.029_bib52","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib53","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.029_bib54","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.029_bib55","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1021\/ja3115696","article-title":"Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils","volume":"135","author":"Palhano","year":"2013","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.clml.2019.03.029_bib56","author":"Hegenbart"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:22Z","timestamp":1761870802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018316732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2152265018316732"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.029","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}